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defined as the ratio between ERR for photon /electron, 
photon/DS and photon/IMPT. 
 
 
Results: Regardless of dose-risk model applied, the 
conformal photons were ranked with the highest ERR for all 
cardiac toxicities, whereas IMPT was ranked with the lowest 
(Figure 1a). For cardiac mortality the ERR for photon was 8.1 
(95 % CI: 3.4 to 30.5), while ERR for IMPT were 1.3 (95 % CI: 
1.1 to 2.4). For cardiac disorder and cardiac failure the ERR 
for photon was 5.1 (95 % CI: 0.9 to 15.2) and 2.1 (95 % CI: 0.8 
to 4.6), respectively (Linear model). The corresponding 
results for IMPT were 1.2 (95% CI: 1.0 to 1.7) and 1.1 (95 % 
CI: 1.0 to 1.2). Similar trends were found using the LQ model. 
Relative to IMPT, photons lead to a risk of cardiac mortality 
that was a factor of 6.1 higher (range 5.7 to 7.0), cardiac 
disorder a factor of 4.3 higher (range 4.1 to 4.9) and cardiac 




Conclusion: Across different cardiac morbidity endpoints, 
and despite different dose-risk models used, the results of 
our modelling study were consistently in favour of protons. 
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It has long been hypothesized that the propagation of 
circulating tumour cells (CTCs) is a pre-requisite for the 
development of metastases. However, robust technology to 
reliably isolate CTCs and characterise them at the molecular 
level has only become available in recent years. Thus 
repeated blood sampling for CTCs could provide a non-
invasive method of serially reassessing tumour status and 
evolving tumour biology.  
Patients with stage I-III NSCLC are at high risk of developing 
distant metastases after radiotherapy (RT) or chemo-
radiotherapy treatment. With the advent of new technologies 
to enumerate CTCs, the clinical significance of CTCs before, 
during and after RT has become of great interest. In the 
current era of targeted therapy and the development of 
personalised medicine the question still remains as to 
whether CTCs could be used to identify patients most likely 
to benefit from radical RT and prevent the delivery of futile 
cancer treatments and their associated toxicity. Prospective 
clinical trials have shown the prognostic value of CTC 
enumeration in patients with non-small cell lung cancer 
(NSCLC) and small cell lung cancer (SCLC) (1, 2). Although 
CTCs have been used as a surrogate biomarker in hundreds of 
clinical trials, as yet none have been incorporated into 
standard clinical practice. To date there are few published 
studies evaluating CTC’s in patients undergoing radical 
thoracic RT.  
In my talk I will discuss the following:  
•novel platforms available for isolation of CTCs 
•current data on the evaluation of CTCs as a biomarker in 
NSCLC and SCLC patients treated with RT  
•advantages and limitations of CTCs as a biomarker •future 
directions and the prospect of using CTCs to stratify patients 
in clinical trials 
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Radiotherapy is a mainstay of cancer treatment. Due to it 
high efficacy to inactivate cancer stem cells in the primary 
tumor and regional metastases as well as its increasing ability 
to spare normal tissues, it has a proven curative potential in 
